2018
DOI: 10.1111/iju.13800
|View full text |Cite
|
Sign up to set email alerts
|

Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification

Abstract: Objectives To investigate the progression to castration‐resistant prostate cancer after primary androgen deprivation therapy, and to build a simple risk prediction model for primary androgen deprivation therapy patients based on the Japan Cancer of the Prostate Risk Assessment criteria. Methods A total of 602 patients who received primary androgen deprivation therapy were entered into the Korean Cancer Study of the Prostate database. The effect of prognostic factors was determined by multivariate analysis. For… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 34 publications
0
7
0
Order By: Relevance
“…However, eventually the tumors usually become hormone‐refractory after long‐term treatment, and at this stage, efficient therapies are not available . The prognosis of PCa is mainly affected by cancer metastasis . Hence, finding new therapeutic approaches to inhibiting tumor cell metastasis is urgently required.…”
Section: Introductionmentioning
confidence: 99%
“…However, eventually the tumors usually become hormone‐refractory after long‐term treatment, and at this stage, efficient therapies are not available . The prognosis of PCa is mainly affected by cancer metastasis . Hence, finding new therapeutic approaches to inhibiting tumor cell metastasis is urgently required.…”
Section: Introductionmentioning
confidence: 99%
“…[20] In high-risk patients treated with primary ADT, >80% of the cohort progressed to CRPC at 5 years after the initiation of ADT. [21] In the CHAARTED and LATITUDE trials, patients treated with upfront chemotherapy and androgen receptor targeting agents had a better OS than those treated with ADT alone. [22] Combination therapies with ADT affect multiple signaling pathways with antitumor effects, [23] suggesting that ADT alone is insufficient to cure prostate cancer.…”
Section: Discussionmentioning
confidence: 99%
“…ADT can result in castration resistance within 2 to 3 years by triggering androgen receptor mutation, amplification, and the development of variants [20] . In high-risk patients treated with primary ADT, >80% of the cohort progressed to CRPC at 5 years after the initiation of ADT [21] . In the CHAARTED and LATITUDE trials, patients treated with upfront chemotherapy and androgen receptor targeting agents had a better OS than those treated with ADT alone [22] .…”
Section: Discussionmentioning
confidence: 99%
“…Choi et al (2018) divided 602 patients of CRPC into three risk groups by assigning a score based on various attributes like age, BMI, Charlson Comorbidity Index, T , N , M , location of metastasis, etc. The multivariate analysis was used for determining the effect of all the attributes.…”
Section: Related Workmentioning
confidence: 99%